AVTR Stock Overview
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$31.61|
|52 Week High||US$44.37|
|52 Week Low||US$28.64|
|1 Month Change||-3.27%|
|3 Month Change||-0.032%|
|1 Year Change||-10.61%|
|3 Year Change||66.63%|
|5 Year Change||n/a|
|Change since IPO||118.00%|
Recent News & Updates
Here's Why Avantor (NYSE:AVTR) Can Manage Its Debt Responsibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Avantor: Narrowing The Relative Valuation Gap
Avantor’s pricing power has allowed it to outpace the inflationary headwinds. Cash flow remains strong, and thus, the balance sheet deleveraging is on track, allowing for future M&A optionality. The stock trades below peers, but should converge over time as the company unlocks its earnings growth potential.
I Ran A Stock Scan For Earnings Growth And Avantor (NYSE:AVTR) Passed With Ease
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|AVTR||US Life Sciences||US Market|
Return vs Industry: AVTR exceeded the US Life Sciences industry which returned -17.5% over the past year.
Return vs Market: AVTR exceeded the US Market which returned -21.2% over the past year.
|AVTR Average Weekly Movement||5.8%|
|Life Sciences Industry Average Movement||11.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: AVTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AVTR's weekly volatility (6%) has been stable over the past year.
About the Company
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies.
Avantor Fundamentals Summary
|AVTR fundamental statistics|
Is AVTR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVTR income statement (TTM)|
|Cost of Revenue||US$4.97b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 28, 2022
|Earnings per share (EPS)||0.88|
|Net Profit Margin||7.08%|
How did AVTR perform over the long term?See historical performance and comparison
Is AVTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AVTR?
Other financial metrics that can be useful for relative valuation.
|What is AVTR's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does AVTR's PE Ratio compare to its peers?
|AVTR PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
MTD Mettler-Toledo International
WST West Pharmaceutical Services
Price-To-Earnings vs Peers: AVTR is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the peer average (30x).
Price to Earnings Ratio vs Industry
How does AVTR's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: AVTR is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the US Life Sciences industry average (30.3x)
Price to Earnings Ratio vs Fair Ratio
What is AVTR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||36.1x|
|Fair PE Ratio||28.7x|
Price-To-Earnings vs Fair Ratio: AVTR is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).
Share Price vs Fair Value
What is the Fair Price of AVTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AVTR ($31.61) is trading above our estimate of fair value ($27.06)
Significantly Below Fair Value: AVTR is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: AVTR is poor value based on its PEG Ratio (1.6x)
Discover undervalued companies
How is Avantor forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVTR's forecast earnings growth (23% per year) is above the savings rate (1.9%).
Earnings vs Market: AVTR's earnings (23% per year) are forecast to grow faster than the US market (13.6% per year).
High Growth Earnings: AVTR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AVTR's revenue (6.3% per year) is forecast to grow slower than the US market (8.2% per year).
High Growth Revenue: AVTR's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVTR's Return on Equity is forecast to be high in 3 years time (21.9%)
Discover growth companies
How has Avantor performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVTR has high quality earnings.
Growing Profit Margin: AVTR's current net profit margins (7.1%) are higher than last year (2.5%).
Past Earnings Growth Analysis
Earnings Trend: AVTR has become profitable over the past 5 years, growing earnings by 83.6% per year.
Accelerating Growth: AVTR's earnings growth over the past year (216.2%) exceeds its 5-year average (83.6% per year).
Earnings vs Industry: AVTR earnings growth over the past year (216.2%) exceeded the Life Sciences industry 21%.
Return on Equity
High ROE: AVTR's Return on Equity (13.7%) is considered low.
Discover strong past performing companies
How is Avantor's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AVTR's short term assets ($2.6B) exceed its short term liabilities ($1.4B).
Long Term Liabilities: AVTR's short term assets ($2.6B) do not cover its long term liabilities ($8.0B).
Debt to Equity History and Analysis
Debt Level: AVTR's net debt to equity ratio (149.3%) is considered high.
Reducing Debt: AVTR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: AVTR's debt is not well covered by operating cash flow (14.4%).
Interest Coverage: AVTR's interest payments on its debt are well covered by EBIT (4.6x coverage).
Discover healthy companies
What is Avantor current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVTR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AVTR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Stubblefield (49 yo)
Mr. Michael Stubblefield has been President, Chief Executive Officer and Director of Avantor, Inc. since 2014. Mr. Stubblefield has been the Chief Executive Officer of Avantor Performance Materials LLC. si...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD13.26M) is about average for companies of similar size in the US market ($USD13.34M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Experienced Management: AVTR's management team is considered experienced (3.8 years average tenure).
Experienced Board: AVTR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AVTR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Avantor, Inc.'s employee growth, exchange listings and data sources
- Name: Avantor, Inc.
- Ticker: AVTR
- Exchange: NYSE
- Founded: 1904
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$19.293b
- Shares outstanding: 610.34m
- Website: https://www.avantorsciences.com
Number of Employees
- Avantor, Inc.
- Radnor Corporate Center
- Building One
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/04 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.